Morphological and molecular motifs of fibrosing pulmonary injury patterns

Journal of Pathology: Clinical Research

Volumn 5, Issue 4, 2019, Pages 256-271

  Jonigk, Danny ^a   Stark, Helge ^a   Braubach, Peter ^a   Neubert, Lavinia ^a   Shin, Hoen oh ^a   Izykowski, Nicole ^a   Welte, Tobias ^a   Janciauskiene, Sabina ^a   Warnecke, Gregor ^a   Haverich, Axel ^a   Kuehnel, Mark ^a   Laenger, Florian ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

alveolar fibroelastosis; idiopathic interstitial pneumonia; interstitial lung diseases; non specific interstitial pneumonia; organising pneumonia; usual interstitial pneumonia

Indexed keywords

BIOLOGICAL MARKER; FORKHEAD TRANSCRIPTION FACTOR; RANTES; TRANSCRIPTOME;

ADULT; AIRWAY REMODELING; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; ENDOCARDIAL FIBROELASTOSIS; FEMALE; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERMETHOD COMPARISON; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LASER MICRODISSECTION; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; MORPHOLOGY; NON SPECIFIC INTERSTITIAL PNEUMONIA; ORGANIZING PNEUMONIA; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; USUAL INTERSTITIAL PNEUMONIA; GENETICS; MIDDLE AGED; PATHOLOGY;

ADULT; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; PULMONARY FIBROSIS; TRANSCRIPTOME;

EID: 85073930430     PISSN: None     EISSN: 20564538     Source Type: Journal    
DOI: 10.1002/cjp2.141     Document Type: Article

References (71)

1. Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013; 188: 733–748.
2. Lee EY. Interstitial lung disease in infants: new classification system, imaging technique, clinical presentation and imaging findings. Pediatr Radiol 2013; 43: 3–13.
3. Homolka J. Idiopathic pulmonary fibrosis: a historical review. CMAJ 1987; 137: 1003–1005.
4. Liebow AA, Steer A, Billingsley JG. Desquamative interstitial pneumonia. Am J Med 1965; 39: 369–404.
5. Carrington CB, Liebow AA. Limited forms of angiitis and granulomatosis of Wegener's type. Am J Med 1966; 41: 497–527.
6. Liebow AA, Carrington CB. Hypersensitivity reactions involving the lung. Trans Stud Coll Physicians Phila 1966; 34: 47–70.
7. Carrington CB, Addington WW, Goff AM, et al. Chronic eosinophilic pneumonia. N Engl J Med 1969; 280: 787–798.
8. Spagnolo P, Lee JC, Sverzellati N, et al. The lung in rheumatoid arthritis – focus on interstitial lung disease. Arthritis Rheumatol 2018; 70: 1544–1554.
9. Rossi G, Cavazza A, Colby TV. Pathology of sarcoidosis. Clin Rev Allergy Immunol 2015; 49: 36–44.
10. Cottin V. Idiopathic interstitial pneumonias with connective tissue diseases features: a review. Respirology 2016; 21: 245–258.
11. Ferri C, Manfredi A, Sebastiani M, et al. Interstitial pneumonia with autoimmune features and undifferentiated connective tissue disease. Autoimmun Rev 2016; 15: 61–70.
12. Lederer DJ, Martinez FJ. Idiopathic pulmonary fibrosis. N Engl J Med 2018; 378: 1811–1823.
13. Kaur A, Mathai SK, Schwartz DA. Genetics in idiopathic pulmonary fibrosis pathogenesis, prognosis, and treatment. Front Med 2017; 4: 154.
14. Larsen BT, Smith ML, Elicker BM, et al. Diagnostic approach to advanced fibrotic interstitial lung disease: bringing together clinical, radiologic, and histologic clues. Arch Pathol Lab Med 2017; 141: 901–915.
15. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788–824.
16. Lettieri CJ, Veerappan GR, Helman DL, et al. Outcomes and safety of surgical lung biopsy for interstitial lung disease. Chest 2005; 127: 1600–1605.
17. Kreider ME, Hansen-Flaschen J, Ahmad NN, et al. Complications of video-assisted thoracoscopic lung biopsy in patients with interstitial lung disease. Ann Thorac Surg 2007; 83: 1140–1144.
18. Blackhall V, Asif M, Renieri A, et al. The role of surgical lung biopsy in the management of interstitial lung disease: experience from a single institution in the UK. Interact Cardiovasc Thorac Surg 2013; 17: 253–257.
19. Hutchinson JP, McKeever TM, Fogarty AW, et al. Surgical lung biopsy for the diagnosis of interstitial lung disease in England: 1997–2008. Eur Respir J 2016; 48: 1453–1461.
20. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071–2082.
21. Hutchinson J, Fogarty A, Hubbard R, et al. Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. Eur Respir J 2015; 46: 795–806.
22. Jonigk D, Rath B, Borchert P, et al. Comparative analysis of morphological and molecular motifs in bronchiolitis obliterans and alveolar fibroelastosis after lung and stem cell transplantation. J Pathol Clin Res 2016; 3: 17–28.
23. Hutchinson JP, McKeever TM, Fogarty AW, et al. Increasing global mortality from idiopathic pulmonary fibrosis in the twenty-first century. Ann Am Thorac Soc 2014; 11: 1176–1185.
24. Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med 2018; 198: e44–e68.
25. Kim SY, Diggans J, Pankratz D, et al. Classification of usual interstitial pneumonia in patients with interstitial lung disease: assessment of a machine learning approach using high-dimensional transcriptional data. Lancet Respir Med 2015; 3: 473–482.
26. Xu W, Xiao Y, Liu H, et al. Nonspecific interstitial pneumonia: clinical associations and outcomes. BMC Pulm Med 2014; 14: 175.
27. Belloli EA, Beckford R, Hadley R, et al. Idiopathic non-specific interstitial pneumonia. Respirology 2016; 21: 259–268.
28. Kono M, Nakamura Y, Yoshimura K, et al. Nonspecific interstitial pneumonia preceding diagnosis of collagen vascular disease. Respir Med 2016; 117: 40–47.
29. Nunes H, Schubel K, Piver D, et al. Nonspecific interstitial pneumonia: survival is influenced by the underlying cause. Eur Respir J 2015; 45: 746–755.
30. Feinstein MB, DeSouza SA, Moreira AL, et al. A comparison of the pathological, clinical and radiographical, features of cryptogenic organising pneumonia, acute fibrinous and organising pneumonia and granulomatous organising pneumonia. J Clin Pathol 2015; 68: 441–447.
31. Baque-Juston M, Pellegrin A, Leroy S, et al. Organizing pneumonia: what is it? A conceptual approach and pictorial review. Diagn Interv Imaging 2014; 95: 771–777.
32. Izykowski N, Kuehnel M, Hussein K, et al. Organizing pneumonia in mice and men. J Transl Med 2016; 14: 169.
33. Khiroya R, Macaluso C, Montero MA, et al. Pleuroparenchymal fibroelastosis: A review of histopathologic features and the relationship between histologic parameters and survival. Am J Surg Pathol 2017; 41: 1683–1689.
34. Rosenbaum JN, Butt YM, Johnson KA, et al. Pleuroparenchymal fibroelastosis: a pattern of chronic lung injury. Hum Pathol 2015; 46: 137–146.
35. Selman M, Pardo A. Revealing the pathogenic and aging-related mechanisms of the enigmatic idiopathic pulmonary fibrosis. An integral model. Am J Respir Crit Care Med 2014; 189: 1161–1172.
36. von der Thüsen JH, Hansell DM, Tominaga M, et al. Pleuroparenchymal fibroelastosis in patients with pulmonary disease secondary to bone marrow transplantation. Mod Pathol 2011; 24: 1633–1639.
37. Jonigk D, Merk M, Hussein K, et al. Obliterative airway remodeling: molecular evidence for shared pathways in transplanted and native lungs. Am J Pathol 2011; 178: 599–608.
38. Jonigk D, Golpon H, Bockmeyer CL, et al. Plexiform lesions in pulmonary arterial hypertension: composition, architecture, and microenvironment. Am J Pathol 2011; 179: 167–179.
39. Jonigk D, Lehmann U, Stuht S, et al. Recipient-derived neoangiogenesis of arterioles and lymphatics in quilty lesions of cardiac allografts. Transplantation 2007; 84: 1335–1342.
40. Jonigk D, Izykowski N, Rische J, et al. Molecular profiling in lung biopsies of human pulmonary allografts to predict chronic lung allograft dysfunction. Am J Pathol 2015; 185: 3178–3188.
41. Bockmeyer CL, Jonigk D, Kreipe H, et al. MicroRNA profiling using RNA from microdissected immunostained tissue. Methods Mol Biol 2011; 755: 85–94.
42. R Core Team. R: A Language and environment for Statistical Computing. R Foundation for Statistical Computing: Vienna, Austria, 2019.
43. Kuhn M, Wing J, Weston S, et al. caret: Classification and Regression Training. 2017
44. Cerdeira JO, Silva PD, Cadimo J, et al. subselect: Selecting Variable Subsets. R package version 0.13. 2017
45. Krämer A, Green J, Pollard J, et al. Causal analysis approaches in ingenuity pathway analysis. Bioinformatics 2014; 30: 523–530.
46. Raghu G, Selman M. Nintedanib and pirfenidone. New antifibrotic treatments indicated for idiopathic pulmonary fibrosis offer hopes and raises questions. Am J Respir Crit Care Med 2015; 191: 252–254.
47. Hayton C, Chaudhuri N. Current treatments in the management of idiopathic pulmonary fibrosis: pirfenidone and nintedanib. Clin Med Insights Ther 2017; 9: 1179559X1771912.
48. Margaritopoulos GA, Vasarmidi E, Antoniou KM. Pirfenidone in the treatment of idiopathic pulmonary fibrosis: an evidence-based review of its place in therapy. Core Evid 2016; 11: 11–22.
49. Wells AU, Costabel U, Poletti V, et al. Challenges in IPF diagnosis, current management and future perspectives. Sarcoidosis Vasc Diffuse Lung Dis 2015; 32: 28–35.
50. Mäkelä K, Hodgson U, Piilonen A, et al. Analysis of the histologic features associated with Interobserver variation in idiopathic pulmonary fibrosis. Am J Surg Pathol 2018; 42: 672–678.
51. Hashisako M, Tanaka T, Terasaki Y, et al. Interobserver agreement of usual interstitial pneumonia diagnosis correlated with patient outcome. Arch Pathol Lab Med 2016; 140: 1375–1382.
52. Jonigk D, Theophile K, Hussein K, et al. Obliterative airway remodelling in transplanted and non-transplanted lungs. Virchows Arch 2010; 457: 369–380.
53. Marjański T, Halman J, Taniewska S, et al. Open lung biopsy performed in idiopathic pulmonary fibrosis is a safe procedure. Kardiochirurgia Torakochirurgia Pol 2017; 14: 236–240.
54. Xu J, Mora A, Shim H, et al. Role of the SDF-1/CXCR4 axis in the pathogenesis of lung injury and fibrosis. Am J Respir Cell Mol Biol 2007; 37: 291–299.
55. Molon B, Gri G, Bettella M, et al. T cell costimulation by chemokine receptors. Nat Immunol 2005; 6: 465–471.
56. Pardo A, Cabrera S, Maldonado M, et al. Role of matrix metalloproteinases in the pathogenesis of idiopathic pulmonary fibrosis. Respir Res 2016; 17: 23.
57. Giannandrea M, Parks WC. Diverse functions of matrix metalloproteinases during fibrosis. Dis Model Mech 2014; 7: 193–203.
58. Epler GR, Colby TV, McLoud TC, et al. Bronchiolitis obliterans organizing pneumonia. N Engl J Med 1985; 312: 152–158.
59. Nagasawa T. CXC chemokine ligand 12 (CXCL12) and its receptor CXCR4. J Mol Med 2014; 92: 433–439.
60. Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science 2015; 348: 74–80.
61. Zheng H, Fu G, Dai T, et al. Migration of endothelial progenitor cells mediated by stromal cell-derived factor-1α/cxcr4 via Pi3k/akt/enos signal transduction pathway. J Cardiovasc Pharmacol 2007; 50: 274–280.
62. Smith M, Dalurzo M, Panse P, et al. Usual interstitial pneumonia-pattern fibrosis in surgical lung biopsies. Clinical, radiological and histopathological clues to aetiology. J Clin Pathol 2013; 66: 896–903.
63. Strieter RM, Gomperts BN, Keane MP. The role of CXC chemokines in pulmonary fibrosis. J Clin Invest 2007; 117: 549–556.
64. Barratt S, Millar A. Vascular remodelling in the pathogenesis of idiopathic pulmonary fibrosis. QJM 2014; 107: 515–519.
65. Pardo A, Selman M. Matrix metalloproteases in aberrant fibrotic tissue remodeling. Proc Am Thorac Soc 2006; 3: 383–388.
66. Craig VJ, Zhang L, Hagood JS, et al. Matrix metalloproteinases as therapeutic targets for idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 2015; 53: 585–600.
67. Selman M, Ruiz V, Cabrera S, et al. TIMP-1, -2, -3, and -4 in idiopathic pulmonary fibrosis. A prevailing nondegradative lung microenvironment? Am J Physiol Cell Mol Physiol 2000; 279: L562–L574.
68. Raghu G, Flaherty KR, Lederer DJ, et al. Use of a molecular classifier to identify usual interstitial pneumonia in conventional transbronchial lung biopsy samples: a prospective validation study. Lancet Respir Med 2019; 7: 487–496.
69. Lee J, Arisi I, Puxeddu E, et al. Bronchoalveolar lavage (BAL) cells in idiopathic pulmonary fibrosis express a complex pro-inflammatory, pro-repair, angiogenic activation pattern, likely associated with macrophage iron accumulation. PLoS One 2018; 13: e0194803.
70. Foster MW, Morrison LD, Todd JL, et al. Quantitative proteomics of bronchoalveolar lavage fluid in idiopathic pulmonary fibrosis. J Proteome Res 2015; 14: 1238–1249.
71. DeBoer EM, Wagner BD, Popler J, et al. Novel application of aptamer proteomic analysis in cystic fibrosis bronchoalveolar lavage fluid. Proteomics Clin Appl 2019; 13: e1800085.